STOCK TITAN

Cadrenal Therapeutics (CVKD) DEF 14A Filings

CVKD NASDAQ

Here are the DEF 14A proxy statements from Cadrenal Therapeutics, Inc. (CVKD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CVKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CVKD filings page.

Rhea-AI Summary

Cadrenal Therapeutics, Inc. is asking stockholders to vote at a virtual 2026 annual meeting on several governance and capital proposals.

Items include electing one Class I director, ratifying WithumSmith+Brown, PC as auditor for 2026, and amending the 2022 Successor Equity Incentive Plan to add 323,542 shares, bringing the plan reserve to 1,000,000 shares. Stockholders are also asked to approve, under Nasdaq Rule 5635(d), the potential issuance of up to 960,000 shares upon exercise of Series C-1 warrants issued in a July 1, 2026 private placement, and to permit adjournment if more time is needed to solicit votes on the equity plan or warrant proposals. There were 3,567,592 shares of common stock outstanding and entitled to vote as of July 27, 2026, and the board recommends voting FOR all proposals.